#hepatocellular carcinoma

Hepatocellular carcinoma can still occur after hepatitis C is cured, and risk factors differ for people with and without cirrhosis.

Over the next two decades, obesity-linked NASH will lead to more deaths and high cost in the United States.

Research has shown that elevated levels of iron in the blood from hereditary hemochromatosis can raise the risk of HCC.

Less than 10% of people with cirrhosis were regularly monitored for liver cancer.

People with fatty liver disease and advanced fibrosis also had a greater incidence of diabetes.

From 1995 to 2016, hepatocellular carcinoma incidence in rural populations climbed by 218%.

Cirrhosis severity and CD4 cell counts were linked to a greater chance of developing liver cancer.

From 1992 to 2018, liver cancer cases related to hepatitis C fell in Japan.

Use of cholesterol-lowering medications was also associated with reduced mortality from liver cancer and other causes.

An advisory panel reviewed follow-up data on checkpoint inhibitors, voting to maintain four approvals and rescind two.

In a small study, 80% of participants treated with Cabometyx and Opdivo underwent successful surgery.

People treated with direct-acting antivirals had better overall survival than those whose hepatitis C remained untreated.

But a simple improvement in dietary intake reversed fatty liver disease and staved off cancer.

Sintilimab plus chemotherapy infused into a liver artery may offer the chance for a cure.

Disruptions in access to treatment and harm reduction services could set back effort to eliminate hep C in the U.S.

Coffee drinkers appear to have a 49% lower risk of dying of chronic liver disease.